Avalo Therapeutics, Inc.
AVTX
Rank in Stocks
#13436
Avalo Therapeutics, Inc. is a precision medicine company in the clinical... Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Share Price
$7.27
Last synced: 2026-11-09
Market Cap
$389.89M
Change (1 day)
4.91%
Change (1 year)
-53.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Avalo Therapeutics, Inc. (AVTX)
Category
Healthcare
EPS for Avalo Therapeutics, Inc. (AVTX)
EPS as of September 2026 TTM: $-2.89
According to Avalo Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-2.89. At the end of 2025 the company had an EPS of $-5.84, a decrease compared to its 2024 EPS of $-4.32.
EPS history for Avalo Therapeutics, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.89 | -50.51% |
| 2025 | $-5.84 | 35.19% |
| 2024 | $-4.32 | -96.20% |
| 2023 | $-113.58 | -89.31% |
| 2022 | $-1.06K | -54.41% |
| 2021 | $-2.33K | -7.65% |
| 2020 | $-2.52K | 207.87% |
| 2019 | $-819.74 | -75.29% |
| 2018 | $-3.32K | -278.65% |
| 2017 | $1.86K | -8,567.31% |
| 2016 | $-21.93 | 35.29% |
| 2015 | $-16.21 | -61.04% |
| 2014 | $-41.61 | -3.50% |
| 2013 | $-43.12 | -78.42% |
| 2012 | $-199.77 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -641.87% |
US
|
|
| $-7.07 | 144.64% |
US
|
|
| $-5.29 | 83.04% |
AU
|
|
| $12.88 | -545.68% |
BE
|
|
| $21.56 | -846.02% |
NL
|
Questions about Avalo Therapeutics, Inc.'s earnings per share (EPS)
What is Avalo Therapeutics, Inc.'s earnings per share (EPS)?
Avalo Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-2.89, as of Sep 2026.
What was Avalo Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Avalo Therapeutics, Inc.'s earnings per share (EPS) was $-5.84, compared with $-4.32 in 2024.
How has Avalo Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Avalo Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-4.32) and lowest in 2020 ($-2.52K).
How does Avalo Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Avalo Therapeutics, Inc.'s earnings per share (EPS) ($-2.89) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.